

November 4, 2009



SCYNEXIS Receives Merck Research Collaboration Milestone Payment

RESEARCH TRIANGLE PARK, N.C. & DULUTH, Ga.--(BUSINESS WIRE)-- Merck Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merck Limited, which began in 2005. SCYNEXIS, a premier drug discovery and development company, focuses considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET efforts towards Merck's animal health discovery efforts.

"Merck is excited about the continued success of our pharmaceutical discovery program. Together with Scynexis we have reached another milestone in our program that focuses on designing novel compounds that specifically address animal health needs," said Dr. Peter Hanson, Head of Pharmaceutical R&D, of Merck.

"SCYNEXIS is pleased to have reached another important milestone in the discovery of animal health solutions with our valued partner Merck," said SCYNEXIS President and CEO Dr. Yves Ribeill. "The achievement of this milestone, which is the third associated with the agreement, demonstrates SCYNEXIS' ability to bring innovation to the animal health pharmaceutical area."

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. SCYNEXIS' mission is to be the leader in delivering effective and innovative drug pipeline solutions to its pharmaceutical partners.

SCYNEXIS research teams integrate medicinal chemistry, advanced biological screening, computational chemistry, bioanalysis and analytical chemistry and use powerful, proprietary technologies such as the HEOS(R) Software Suite and MEDCHEM-FACTORY(R) to advance molecules to candidate selection. SCYNEXIS development teams have been tailored to be especially effective in moving customer projects from the discovery phase to the clinic. SCYNEXIS process chemistry and bioanalytical departments operate under current GMP/GLP guidelines and have a strong track record of success. www.scynexis.com

(R)HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc.

Le texte du communiqué issu d'une traduction ne doit d'aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d'origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.